Sociedad Americana de Hirudoterapia

Past, present and future of hirudin

Research article published in Haemostasis (1991)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosMarkwardt F et al. · Haemostasis, 1991

Abstract

The naturally occurring anticoagulant from medicinal leeches, hirudin, which we isolated and biochemically analyzed 30 years ago as a miniprotein with specific antithrombin activity, has afterwards been employed for scientific and diagnostic purposes in hematology. Pure hirudin proved to be an antithrombotic agent of high quality that displays an antithrombotic action dependent upon its blood level. After intravenous injection, it is distributed in the extracellular space and is almost completely eliminated through the kidneys by glomerular filtration in a biologically active form. The efficacy of hirudin in preventing venous and arterial thrombosis and disseminated intravascular coagulation was demonstrated in various animal models. Clinical pharmacological studies corroborated the specific pharmacodynamic and pharmacokinetic properties of hirudin found in animal experiments. Genetic engineering led to the availability of sufficient quantities of recombinant hirudin (r-hirudin) for clinical purposes. Pharmacologic profiling of r-hirudin showed that both its pharmacokinetic and pharmacodynamic characteristics are very similar to those of native hirudin. Clinical pharmacological studies with r-hirudin revealed that, at single therapeutically relevant doses, r-hirudin is a well-tolerated and potent anticoagulant without any detectable side effects and allergic reactions. Further preclinical studies of r-hirudin should concentrate on identifying possible indications for use, on the development of r-hirudin preparations and derivatives, and on the development of antidotes for hirudin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeHistorical ArticleJournal ArticleResearch Support, U.S. Gov't, P.H.S.Review
Indexed MeSH termsAmino Acid SequenceAnimalsDisseminated Intravascular CoagulationDogsFibrinolytic AgentsHirudin TherapyHirudinsHistory, 20th CenturyHumansLeechesMolecular Sequence DataRabbits

Resumen

Past, present and future of hirudin.

Por qué esto importa para la hirudoterapia

This article reviews the historical isolation, pharmacological profiling, and future clinical potential of hirudin, the naturally occurring anticoagulant found in medicinal leeches. It highlights hirudin's transition from a scientific reagent to a high-quality antithrombotic agent, noting its renal clearance, extracellular distribution, and the development of well-tolerated recombinant formulations (r-hirudin) devoid of allergic side effects. This review is inherently central to the ASH domain, providing a comprehensive historical and pharmacological overview of the most famous leech-derived therapeutic. The caveat is that this is a historical review focused on the isolated and

Citación

Past, present and future of hirudin

Markwardt F et al. · Haemostasis, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.